Efficacy of amifostine in protection against doxorubicin-induced acute cardiotoxic effects in rats

Background/Aim. Amifostine (AMI) is a broad-spectrum cytoprotector which protects against variety of radio- and chemotherapy-related toxicities without decreasing their antitumor action. The aim of the study was to investigate the potential protective effects of AMI against acute cardiotoxic eff...

Full description

Saved in:
Bibliographic Details
Main Authors: Dragojević-Simić Viktorija, Dobrić Silva, Jaćević Vesna, Bokonjić Dubravko, Milosavljević Ivica, Kovačević Aleksandra, Mikić Dragan
Format: Article
Language:English
Published: Ministry of Defence of the Republic of Serbia, University of Defence, Belgrade 2013-01-01
Series:Vojnosanitetski Pregled
Subjects:
Online Access:http://www.doiserbia.nb.rs/img/doi/0042-8450/2013/0042-84501200041D.pdf
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850234765976797184
author Dragojević-Simić Viktorija
Dobrić Silva
Jaćević Vesna
Bokonjić Dubravko
Milosavljević Ivica
Kovačević Aleksandra
Mikić Dragan
author_facet Dragojević-Simić Viktorija
Dobrić Silva
Jaćević Vesna
Bokonjić Dubravko
Milosavljević Ivica
Kovačević Aleksandra
Mikić Dragan
author_sort Dragojević-Simić Viktorija
collection DOAJ
description Background/Aim. Amifostine (AMI) is a broad-spectrum cytoprotector which protects against variety of radio- and chemotherapy-related toxicities without decreasing their antitumor action. The aim of the study was to investigate the potential protective effects of AMI against acute cardiotoxic effects of doxorubicin (DOX) in male Wistar rats. Methods. AMI (300 mg/kg ip) was given 30 min before DOX (6 mg/kg and 10mg/kg b.w., iv). The evaluation of DOXinduced cardiotoxic effects, as well as cardioprotective efficacy of AMI was performed 48 h after their administration by determining serum activities of enzymes known to be markers of cardiac damage (creatine kinase - CK, aspartate aminotransferase - AST, lactate dehydrogenase - LDH, and its isoenzyme α-hydroxybutirate dehydrogenase - α- HBDH), as well as the histopathological and ultrastructural analysis of the heart tissue. Results. AMI successfully prevented a significant increase in serum activity of CK, AST, LDH and α-HBDH in animals treated with DOX in the dose of 6 mg/kg (121.14 ± 18.37 vs 167.70 ± 44.24; 771.42 ± 161.99 vs 1057.00 ± 300.00; 3230.00 ± 1031.73 vs 4243.10 ± 904.06; 202.57 ± 42.46 vs 294.90 ± 80.20 UI/l, respectively), and ameliorated DOX-induced structural damage of the rat myocardium. Pretreatment with AMI in rats given 10 mg/kg DOX reduced the cardiac damage score (CDS) from 2.62 ± 0.51 to 1.62 ± 0.51, i.e. to the CDS value obtained with the lower dose of DOX (6 mg/kg). The ultrastructural analysis of the rat myocardium showed that AMI successfully protected the sarcolemma of cardiomyocytes and reduced mitochondria damage induced by DOX given in the dose of 6 mg/kg. Besides, capillaries were less morphologically changed and apoptosis of endothelial cells was extremely rare in AMI-protected animals. AMI itself did not cause any prominent changes in the examined parameters in comparison with the control rats. Conclusion. AMI provided a significant protection against DOX-induced acute cardiotoxic effects in rats. This finding implies its potential to be a successful cardioprotector in patients treated with DOX due to malignant diseases.
format Article
id doaj-art-0f87e84bb5a849678e8b8bf86bb36ea0
institution OA Journals
issn 0042-8450
language English
publishDate 2013-01-01
publisher Ministry of Defence of the Republic of Serbia, University of Defence, Belgrade
record_format Article
series Vojnosanitetski Pregled
spelling doaj-art-0f87e84bb5a849678e8b8bf86bb36ea02025-08-20T02:02:32ZengMinistry of Defence of the Republic of Serbia, University of Defence, BelgradeVojnosanitetski Pregled0042-84502013-01-01701384510.2298/VSP110905041DEfficacy of amifostine in protection against doxorubicin-induced acute cardiotoxic effects in ratsDragojević-Simić ViktorijaDobrić SilvaJaćević VesnaBokonjić DubravkoMilosavljević IvicaKovačević AleksandraMikić DraganBackground/Aim. Amifostine (AMI) is a broad-spectrum cytoprotector which protects against variety of radio- and chemotherapy-related toxicities without decreasing their antitumor action. The aim of the study was to investigate the potential protective effects of AMI against acute cardiotoxic effects of doxorubicin (DOX) in male Wistar rats. Methods. AMI (300 mg/kg ip) was given 30 min before DOX (6 mg/kg and 10mg/kg b.w., iv). The evaluation of DOXinduced cardiotoxic effects, as well as cardioprotective efficacy of AMI was performed 48 h after their administration by determining serum activities of enzymes known to be markers of cardiac damage (creatine kinase - CK, aspartate aminotransferase - AST, lactate dehydrogenase - LDH, and its isoenzyme α-hydroxybutirate dehydrogenase - α- HBDH), as well as the histopathological and ultrastructural analysis of the heart tissue. Results. AMI successfully prevented a significant increase in serum activity of CK, AST, LDH and α-HBDH in animals treated with DOX in the dose of 6 mg/kg (121.14 ± 18.37 vs 167.70 ± 44.24; 771.42 ± 161.99 vs 1057.00 ± 300.00; 3230.00 ± 1031.73 vs 4243.10 ± 904.06; 202.57 ± 42.46 vs 294.90 ± 80.20 UI/l, respectively), and ameliorated DOX-induced structural damage of the rat myocardium. Pretreatment with AMI in rats given 10 mg/kg DOX reduced the cardiac damage score (CDS) from 2.62 ± 0.51 to 1.62 ± 0.51, i.e. to the CDS value obtained with the lower dose of DOX (6 mg/kg). The ultrastructural analysis of the rat myocardium showed that AMI successfully protected the sarcolemma of cardiomyocytes and reduced mitochondria damage induced by DOX given in the dose of 6 mg/kg. Besides, capillaries were less morphologically changed and apoptosis of endothelial cells was extremely rare in AMI-protected animals. AMI itself did not cause any prominent changes in the examined parameters in comparison with the control rats. Conclusion. AMI provided a significant protection against DOX-induced acute cardiotoxic effects in rats. This finding implies its potential to be a successful cardioprotector in patients treated with DOX due to malignant diseases.http://www.doiserbia.nb.rs/img/doi/0042-8450/2013/0042-84501200041D.pdfamifostinedoxorubicinheart drug toxicitycytoprotectionratswistar
spellingShingle Dragojević-Simić Viktorija
Dobrić Silva
Jaćević Vesna
Bokonjić Dubravko
Milosavljević Ivica
Kovačević Aleksandra
Mikić Dragan
Efficacy of amifostine in protection against doxorubicin-induced acute cardiotoxic effects in rats
Vojnosanitetski Pregled
amifostine
doxorubicin
heart drug toxicity
cytoprotection
rats
wistar
title Efficacy of amifostine in protection against doxorubicin-induced acute cardiotoxic effects in rats
title_full Efficacy of amifostine in protection against doxorubicin-induced acute cardiotoxic effects in rats
title_fullStr Efficacy of amifostine in protection against doxorubicin-induced acute cardiotoxic effects in rats
title_full_unstemmed Efficacy of amifostine in protection against doxorubicin-induced acute cardiotoxic effects in rats
title_short Efficacy of amifostine in protection against doxorubicin-induced acute cardiotoxic effects in rats
title_sort efficacy of amifostine in protection against doxorubicin induced acute cardiotoxic effects in rats
topic amifostine
doxorubicin
heart drug toxicity
cytoprotection
rats
wistar
url http://www.doiserbia.nb.rs/img/doi/0042-8450/2013/0042-84501200041D.pdf
work_keys_str_mv AT dragojevicsimicviktorija efficacyofamifostineinprotectionagainstdoxorubicininducedacutecardiotoxiceffectsinrats
AT dobricsilva efficacyofamifostineinprotectionagainstdoxorubicininducedacutecardiotoxiceffectsinrats
AT jacevicvesna efficacyofamifostineinprotectionagainstdoxorubicininducedacutecardiotoxiceffectsinrats
AT bokonjicdubravko efficacyofamifostineinprotectionagainstdoxorubicininducedacutecardiotoxiceffectsinrats
AT milosavljevicivica efficacyofamifostineinprotectionagainstdoxorubicininducedacutecardiotoxiceffectsinrats
AT kovacevicaleksandra efficacyofamifostineinprotectionagainstdoxorubicininducedacutecardiotoxiceffectsinrats
AT mikicdragan efficacyofamifostineinprotectionagainstdoxorubicininducedacutecardiotoxiceffectsinrats